Maximilian Steinhardt, Eli Muchtar, Taxiarchis Kourelis, Rahma Warsame, Michelle Lynn Mauermann, Francis K. Buadi, David Dingli, Nelson Leung, Joselle Cook, Ronald S. Go, Suzanne R. Hayman, Wilson I Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Tamer Hellou, Melinda S.Y. Tan, Houssam Halawi, A C Fonder, Miriam Hobbs, Nadine Abdallah, Y. Lin, Mustaqeem Siddiqui, R. Kyle, K. Martin Kortüm, Hermann Einsele, S Vincent Rajkumar, Shaji Kumar, Morie A. Gertz, Angela Dispenzieri
ABSTRACT: Gastrointestinal (GI) involvement is a clinically relevant but undercharacterized manifestation of systemic light chain amyloidosis (AL). We aimed to define the clinical spectrum, histologic patterns, and outcomes of symptomatic GI involvement in AL. We retrospectively analyzed 4396 patients with AL from 2010 to 2024, of whom 521 (11.9%) had provider-attributed symptomatic GI involvement; 66% had biopsy-proven GI AL. Symptoms most commonly included early satiety (61%), bowel irregularities (58%), nausea (35%), abdominal pain (28%), and dysphagia (23%). Autonomic neuropathy was frequent (43% clinician attributed; 23% via autonomic reflex testing) and contributed to dysmotility-related symptoms, often without GI biopsy positivity. Among 747 GI biopsies, mucosal infiltration predominated (71%) and was associated with bleeding (22% vs 9%), cachexia, and inferior survival, whereas vascular involvement was associated with lower bleeding risk. Combined involvement of mucosa, submucosa, and vessels conferred the worst prognosis (median overall survival [mOS], 2.4 vs 5.1 vs 7.8 years for 3 vs 2 vs 1 layer); mOS was 6.8 years and was primarily driven by cardiac stage and hematologic response (very good partial response [VGPR] or better: hazard ratio, 0.20; 95% CI 0.13-0.32), with more favorable outcomes in patients with isolated GI involvement. Cachexia and persistent diarrhea were the main drivers of morbidity, need for nutritional support, and GI-related mortality (odds ratio, 2.7 for the combined end point). GI bleeding rarely recurred after achieving VGPR or better. Overall, mucosal involvement, cachexia, and dysmotility define clinically meaningful GI AL and support systematic assessment of autonomic dysfunction as well as evaluation of the need for nutritional support as a GI-specific end point for AL trials.